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SETTING: In July 2005, Médecins Sans Frontières and 
the Ministry of Health, Kenya, implemented an integrated 
tuberculosis-human immunodefi  ciency virus (TB-HIV) 
programme in western Kenya.
OBJECTIVE: To evaluate the impact of an integrated 
TB-HIV programme on patient care and TB programme 
outcomes.
DESIGN:  Retrospective evaluation of three time periods: 
before (January–June 2005), shortly after (January–June 
2006) and medium term after (January–December 2007) 
the implementation of the integrated programme.
RESULTS: Respectively 79% and 91% of TB patients 
were HIV tested shortly and at medium term after ser-
vice integration. The HIV-positive rate varied from 96% 
before the intervention to respectively 88% (305/347) 
and 74% (301/405) after. The estimated number of HIV-
positive cases was respectively 303, 323 and 331 in the 
three periods. The proportion of patients receiving co-
trimoxazole prophylaxis increased signifi  cantly  from 
47% (142/303) to 94% (303/323) and 86% (285/331, 
P < 0.05). Before the intervention, 87% (171/197) of 
the TB-HIV patients would have been missed when 
initiating antiretroviral treatment, compared to respec-
tively 29% (60/210) and 36% (78/215) after the inte-
gration. The TB programme success rate increased from 
56% (230/409) to 71% (319/447) in the third period 
(P < 0.05); however, there was no signifi  cant decrease 
in the default rate: 20% to 22% (P = 0.66) and 18% 
(P = 0.37).
CONCLUSION:  Integrated TB-HIV care has a very posi-
tive impact on the management of TB-HIV patients and 
on TB treatment outcomes.
KEY WORDS:  tuberculosis; HIV; one-stop; integration; 
ART
KENYA has one of the highest tuberculosis (TB) bur-
dens in the world, with an incidence of 353 new cases 
per 100 000 population in 2007.1 The overall preva-
lence of human immunodefi  ciency virus (HIV) infec-
tion in the country has been estimated at 7.4%, but 
the geographical distribution is very heterogeneous, 
with the western region accounting for the highest 
prevalence in the country.2 Homa Bay District is lo-
cated in western Kenya, on the shores of Lake Victo-
ria. The estimated HIV prevalence in adults is 24%.3 
The need for collaboration between TB and HIV 
programmes is widely recognised.4 In 2004, the World 
Health Organization (WHO) published guidelines to 
encourage and help the national programmes in the 
implementation of collaborative activities.5 Prior to 
2005, no signifi  cant collaboration was put into prac-
tice in Kenya.6 
In July 2005, Médecins Sans Frontières (MSF), in 
collaboration with the Kenyan Ministry of Health 
(MOH), implemented an integrated TB-HIV manage-
ment programme at the TB clinic of Homa Bay District 
Hospital. The objective of the study was to evaluate 
the short- and medium-term impact of this interven-
tion on HIV testing for TB patients, the management 
of HIV-positive TB patients needing antiretroviral 
treatment (ART) and TB programme outcomes.
METHODS 
Intervention
The implementation of an integrated TB-HIV manage-
ment programme at the TB clinic was achieved fi  rst 
by increasing human resources: three staff members 
(clinical offi  cer, nurse and counsellor) were transferred 
from the HIV clinic to the TB clinic. After integra-
tion, HIV testing and counselling were provided at 
the TB clinic along with education on HIV prevention. 
All services linked to the HIV care of HIV-positive 
TB patients, such as CD4 monitoring, cotrimoxazole 
prophylaxis and ART initiation or continuation, were 
delivered from the TB clinic. 
Population 
All new TB patients registered at the TB clinic in Homa 
Bay District Hospital were included in the study. To 
evaluate the impact of the intervention, the indicators 
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were calculated for the new patients registered in 
the programme during the three periods of time be-
fore (January–June 2005), shortly after (January–June 
2006) and at medium term after (January–December 
2007) the implementation of the integrated services.
Data collection
In this retrospective study, data were collected from 
the TB registers, HIV testing registers and the HIV 
clinic patient fi  les. Data from the TB registers and rel-
evant information from the HIV clinic patient fi  les 
were input into an Excel® database (Microsoft® Offi  ce 
Excel 2003, MicroSoft, Redmond, WA, USA). 
Study end points
The end points for the analysis were the proportion of 
HIV tests performed on new TB patients, the propor-
tion of HIV positivity among patients who underwent 
HIV testing, the estimated proportion of HIV-positive 
TB patients receiving cotrimoxazole prophylaxis, and 
the estimated proportion of patients receiving ART 
by the end of the TB treatment among those who re-
quired it. 
Given that HIV testing was not performed system-
atically during the three study periods, the number of 
HIV-positive TB patients in the programme was esti-
mated using the HIV prevalence among TB patients 
tested for HIV in 2007 in Homa Bay TB Clinic. It 
was also considered that 65% of HIV-positive TB pa-
tients were in need of ART.7
TB programme outcomes were analysed 1 year af-
ter initiating TB treatment over the three time peri-
ods. TB outcomes for patients according to HIV sta-
tus and ART initiation were also analysed for patients 
registered in 2007. 
TB treatment outcomes were defi  ned according to 
WHO guidelines.8 HIV testing was performed using 
two rapid tests in succession, Determine® HIV Rapid 
Test (Abbott Diagnostic Division, Hoofddorp, The 
Netherlands) and Uni-Gold® HIV Rapid Test (Trinity 
Biotech, Bray, Ireland). TB was diagnosed on the basis 
of clinical examinations, sputum smear microscopy 
and, in some cases, chest X-ray. HIV patients were in-
itiated on ART following WHO guidelines.8 
Statistical analysis
Proportion of baseline patient characteristics and 
treatment outcome ratios were calculated using Epi 
Info 6.0 (Centers for Disease Control and Prevention, 
Atlanta, Georgia, USA) for the three different periods. 
Simple proportions and trends were compared be-
tween the three periods using Pearson’s χ2 test. The dif-
ference was signifi  cant if P values were below 0.05. 
Ethical approval was not required for this retro-
spective, record-based study. 
RESULTS
Respectively 409, 437 and 477 patients were regis-
tered in the TB clinic in the three periods of time ana-
lysed. The impact of the intervention on HIV testing 
is shown in Table 1. 
The estimated proportions of HIV-positive TB pa-
tients put under cotrimoxazole prophylaxis and of 
HIV-positive TB patients requiring ART and who ac-
tually received it increased signifi  cantly over the three 
periods of time (Table 2). There was a slight decrease 
in the estimated proportions of patients put on cotri-
moxazole and on ART between the second and third 
periods that was statistically signifi  cant (P = 0.005) 
for cotrimoxazole, but not for ART initiation (P = 
0.18). We can estimate that respectively 162 (53%), 
22 (7%) and 47 (14%) HIV-positive TB patients 
were  missed when prescribing cotrimoxazole, and 
172 (87%), 61 (29%) and 79 (37%) HIV-positive TB 
patients were missed when prescribing ART over the 
three periods of time. 
The proportion of TB smear-negative patients re-
mained stable throughout the study period, at 42% 
(171/409), 37% (160/437) and 40% (177/447); the 
proportion of extra-pulmonary patients increased 
slightly, but signifi  cantly, after the implementation 
of a one-stop service: 22% (89/409), 29% (125/437, 
P < 0.05), 30% (136/447, P < 0.05).
TB treatment outcomes before, shortly after and 
at medium term after the intervention are shown in 
Table 3. There was a signifi  cant increased trend in the 
success rate and decrease in the death rate after the 
implementation of the one-stop service. 
TB treatment outcomes according to HIV status 
Table 1  HIV testing and HIV-positive rates in TB patients 
before, shortly after and at medium term after 
implementing one-stop TB-HIV comprehensive care, 
Homa Bay Hospital, Kenya
Before
(n = 409)
n/N (%)
Shortly
after
(n = 437)
n (%)
Medium 
term
(n = 447)
n (%) P value*
HIV testing rate  NA 347 (79) 405 (91) <0.01
HIV-positive rate  49/51 (96) 305 (88) 301 (74) <0.01
* Comparison between the services shortly after and at medium term after 
integration.
HIV = human immunodeﬁ  ciency virus; TB = tuberculosis; NA = not available.
Table 2  Cotrimoxazole prophylaxis and ART before, shortly 
after and at medium term after intervention in the TB Clinic 
at Homa Bay Hospital, Kenya 
Before
n (%)
Shortly
after
n (%)
Medium 
term
n (%)
Trend 
P value
HIV+ cases 304 325 332
HIV+ patients under 
  cotrimoxazole prophylaxis* 142 (47) 303 (93) 285 (86) <0.01
Patients requiring ART 
 receiving  ART†    26 (9) 150 (46) 137 (41) <0.01
* Patients receiving cotrimoxazole prophylaxis/estimated number of HIV+ 
patients
† Patients under ART/estimated number of TB patients requiring ART. 
ART = antiretroviral treatment; TB = tuberculosis; HIV = human immuno-
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and ART initiation are shown in Table 4. There was 
no difference between the outcomes of HIV-positive 
patients on ART and those of HIV-negative patients. 
The outcomes of the HIV-positive patients not on 
ART and those with unknown HIV status were con-
siderably worse than for the HIV-negative patients.
DISCUSSION
The impact of implementing a one-stop service in 
Homa Bay on HIV testing rates and patient man-
agement has been very positive. Signifi  cant scale-up 
was observed nationwide in HIV testing rates of TB 
patients, from 32% tested immediately after the in-
troduction of a revised TB case recording and report-
ing system in 2005, to 59% 1 year later.6 In a non-
integrated TB setting in South Africa, only 26% of the 
TB patients knew their status;9 where TB and HIV 
services are integrated, this proportion reaches 87% 
in Rwanda10 and 91% in Malawi.11
Having access to onsite HIV testing in the TB clinic 
has clear benefi   ts for TB patients from high HIV 
prevalence areas such as Homa Bay, where three of 
four TB patients are HIV-positive. As is the case with 
other TB programmes,12 HIV testing was only of-
fered to those suspected of HIV before the integra-
tion of services in Homa Bay. A decrease in the HIV-
positive rate among tested patients over time has 
therefore been observed. A limitation of this analysis 
was the fact that the TB registers did not collect HIV 
information before June 2005.
The benefi  ts of cotrimoxazole treatment in HIV-
positive TB patients are well established in Africa.13 
Care for HIV-positive TB patients in Homa Bay clearly 
improved, with considerable increases in the number 
of patients receiving cotrimoxazole prophylaxis and 
ART. Due to the low rate of HIV diagnosis before the 
intervention, the analysis was not able to compare 
the exact proportions of HIV-positive patients receiv-
ing cotrimoxazole or ART before and after the inter-
vention, but it seems that for a considerable number 
of TB patients, the opportunity of starting cotrimox-
azole and ART during TB treatment was missed dur-
ing that period. Nevertheless, after introducing HIV 
care in the TB clinic, the proportions of HIV-positive 
TB patients receiving cotrimoxazole and ART were 
higher than those reported at a national level in Ken-
ya.6 In Zambia, Harris et al. observed an increase of 
38% in ART programme TB-HIV enrolees after inte-
gration of the TB and HIV programmes.14 Consider-
ing that the number of patients with unknown HIV 
status halved between the second and third period of 
time, it is surprising to fi  nd that the proportion of pa-
tients on cotrimoxazole and ART did not increase 
during this period.
A drop in the number of hospital admissions in 
the TB programme was observed in 2007. The num-
ber of TB patients enrolled has remained stable since 
then. Reasons for such a decrease may relate to the 
opening of new TB centres and the increased access 
to ART in the area. 
In addition to the expected positive impact on the 
provision of HIV testing and care, there was an im-
provement in the TB programme outcomes at me-
dium term. As MSF support for the TB programme 
had started long before integration, the collaboration 
between the HIV and TB programmes was probably 
the main infl  uence on these results.15 The increased 
knowledge of new staff members regarding TB-HIV 
co-infection, as well as the experience of both counsel-
ling and drug dispensing brought from the HIV clinic 
into the TB programme, benefi  ted  all TB  patients, 
and not only those who were HIV-positive. The in-
crease in the proportion of extra-pulmonary cases over 
time is likely a result of increased awareness about 
Table 3  TB programme outcomes before, shortly after and 
at medium term after implementing a one-stop TB-HIV service 
in the TB clinic in Homa Bay Hospital, Kenya
Before 
(n = 409)
n (%)
Shortly 
after 
(n = 437)
n (%)
Medium 
term
(n = 447)
n (%)
Trend
P value
Success rate  230 (56) 254 (58) 319 (71) <0.01
Death rate    31 (8)   45 (10)   15 (3) <0.01
Failure  rate    0   5  (1)   6  (1)    0.15
Default rate    82 (20)   93 (21)   79 (18)    0.48
Transfer rate    66 (16)   40 (9)   28 (6) <0.001
TB = tuberculosis; HIV = human immunodeﬁ  ciency virus.
Table 4  TB programme outcomes according to HIV status and ART initiation of patients registered in the TB clinic in 2007, 
Homa Bay Hospital, Kenya
HIV−
(n = 104)
n (%)
HIV+/ART+
(n = 137)
n (%) P1 value*
HIV+/ART−
(n = 164)
n (%) P2 value†
HIV unknown
(n = 42)
n (%) P3 value‡
Success rate  85 (82) 104 (76) 0.27 108 (66) <0.01 22 (52) <0.01
Death  rate   0   2  (1) 0.60   9  (5)    0.04  4  (10) <0.01
Failure  rate   1  (1)   3  (2) 0.81   2  (1)    0.69  0    0.64
Default rate  14 (13)   22 (16) 0.58   30 (18)    0.29 13 (31)    0.01
Transfer  rate   4  (4)   6  (4) 0.90  15  (9)    0.16  3  (7)    0.68
* HIV+ patients on ART compared with HIV-negative patients.
† HIV+ patients not on ART compared with HIV-negative patients.
‡ Patients with HIV status unknown compared with HIV-negative patients.
HIV = human immunodeﬁ  ciency virus; TB = tuberculosis; ART = antiretroviral treatment.614  The   International   Journal   of   Tuberculosis   and   Lung   Disease
this presentation of TB from the clinicians working 
in the TB clinic. Contrary to what has been observed 
in other programmes,16 there was no improvement in 
the default rate after the introduction of HIV care in 
the TB clinic, although adherence counselling for TB 
treatment had been reinforced. Some of the patients 
recorded as defaulters in the second and third period 
may have been transferred to other TB centres. 
Other impacts observed after the intervention 
were improved infection control, secondary to a re-
duction in contact between infectious TB patients 
and immune-compromised HIV patients in the HIV 
clinic; an improvement in the fi  ling system, with the 
use of patient fi  les for HIV-positive TB patients that 
were kept in the chest clinic during TB treatment and 
sent to the HIV clinic at the end of the TB treatment; 
and an improvement in the recording system, with 
better recording of HIV testing results and outcomes 
in the TB register.
The TB treatment outcomes for HIV-positive pa-
tients were not signifi  cantly different from those of 
HIV-negative patients. However, better outcomes were 
observed in HIV-negative patients and HIV-positive 
patients initiated on ART in a timely fashion17,18 
when compared with HIV-positive patients not on 
ART or patients with unknown HIV status. In other 
settings, HIV-positive TB patients receiving ART had 
a risk of death that was six times lower.19 Default 
rates did not change despite specifi   c and intensive 
counselling for patients on ART. Reasons and risk 
factors for defaulters should be further investigated, 
and additional efforts to trace defaulter patients 
should be made. In Nigeria, defaulter rates were simi-
lar to those found in this study, and were not related 
to HIV status.20 The poor outcomes observed in TB 
patients with unknown HIV status once more rein-
force the necessity of HIV testing21 to provide ade-
quate care and ART to HIV-positive TB patients. 
In conclusion, the introduction of HIV testing, 
treatment and care in a TB clinic in a resource-limited 
setting such as Homa Bay has had a positive impact 
on HIV detection among TB patients, on the patient 
management both in the short and medium term, and 
on TB programme success rate at medium term. 
However, the proportion of patients who defaulted 
did not improve. TB treatment outcomes for patients 
with unknown HIV status and for HIV-positive pa-
tients not initiated on ART were signifi  cantly worse 
than for HIV-negative patients. 
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CONTEXTE :    En juillet 2005, Médecins Sans Frontières 
et le Ministère de la Santé ont mis en route un pro-
gramme TB-VIH (tuberculose-virus de l’immunodéfi  -
cience humaine) intégré dans l’Ouest du Kenya.
OBJECTIF :    Evaluer l’impact de ce programme sur les 
soins des patients et les résultats du programme TB.
SCHÉMA :  Evaluation rétrospective de trois périodes de 
temps : avant la mise en œuvre (janvier–juin 2005), peu 
après celle-ci (janvier–juin 2006) et à moyen terme 
après (janvier–décembre 2007).
RÉSULTATS :  Après l’intégration des services, respective-
ment 79% et 91% des patients TB ont été testés pour le 
VIH. Le taux de positivité du VIH a varié de 96% avant 
l’intervention à respectivement 88% (305/347) et 74% 
(301/405) après celle-ci. Le nombre estimé de cas infec-
tés par le VIH ont été respectivement de 303, 323 et 331 
pendant les trois périodes considérées. La proportion de 
patients bénéfi  ciant d’une prophylaxie au cotrimoxazole 
a augmenté d’une manière signifi  cative de 47% (142/ 
303) à 94% (303/323) et 86% (285/331, P < 0,05). 
Avant l’intervention, 87% (171/197) des patients TB-
VIH n’auraient pas été détectés au moment de la mise en 
route du traitement antirétroviral par comparaison avec 
29% (60/210) et 36% (78/215) après l’intégration. Le 
taux de succès du programme TB a augmenté de 56% 
(230/409) à 71% (319/447) pendant la troisième pé-
riode de temps (P < 0,05), alors qu’on ne notait pas de 
diminution signifi  cative du taux d’abandon : 20% vers 
22% (P = 0,66) et 18% (P = 0,37).
CONCLUSION :    Les soins intégrés TB-VIH ont un im-
pact très positif sur la prise en charge des patients TB-
VIH et sur les résultats du traitement de la TB. 
RÉSUMÉ
RESUMEN
MARCO DE REFERENCIA:    En julio del 2005, Médecins 
Sans Frontières y el Ministerio de salud introdujeron el 
programa integrado TB-HIV (tuberculosis y virus de la 
inmunodefi  ciencia humana) en Kenya occidental.
OBJETIVO:    Evaluar la repercusión del nuevo programa 
en la atención de los pacientes y en los resultados del 
programa.
MÉTODOS:    Evaluación retrospectiva de tres períodos: 
antes de la introducción del programa (de enero a junio 
del 2005), un corto tiempo después (de enero a junio del 
2006) y un mediano tiempo después de la introducción 
(de enero a diciembre del 2007). 
RESULTADOS:  La prueba del VIH se practicó en 79% de 
los pacientes tuberculosos que se inscribieron un corto 
tiempo después de la introducción del programa y en 
91% de los inscritos un mediano tiempo después. La 
tasa de positividad de la prueba del VIH osciló entre 
96% antes de la intervención y respectivamente 88% 
(305 de 347) y 74% (301/405) después. El número cal-
culado de casos positivos al VIH fue 303 antes de la in-
troducción de programa integrado y 323 y 331 después. 
La proporción de pacientes que recibieron profi  laxis con 
cotrimoxasol aumentó signifi  cativamente de 47% (142/ 
303) a 94% (303/323) y hasta 86% (285/331; P  < 
0,05). Se calculó que antes de la intervención, se habría 
pasado por alto 87% (171/197) de los pacientes con el 
VIH que estaban coinfectados por TB en el momento de 
iniciar el tratamiento antirretrovírico, en comparación 
con 29% (60/210) y 36% (78/215) después de la integra-
ción del programa. La tasa de éxito del programa anti-
tuberculoso aumentó de 56% (230/409) a 71% (319/ 
447) en el tercer período de análisis (P < 0,05); sin em-
bargo, no hubo una disminución signifi  cativa en la tasa de 
abandonos: 20% a 22% (P = 0,66) y 18% (P = 0,37).
CONCLUSIÓN:    La atención integrada de la TB y la in-
fección por el VIH tiene consecuencias muy positivas en 
el manejo de los pacientes que padecen simultáneamente 
estas enfermedades y en los resultados del tratamiento 
antituberculoso.